Sen. Carper Congratulates Incyte on FDA Approval of Blood Cancer Drug
Incyte developed the drug in Wilmington, Del. after Sen. Carper helped the company locate here.
WILMINGTON – Today, Sen. Tom Carper (D-Del.) congratulated drug company Incyte Corporation on the U.S. Food and Drug Administration (FDA) approving its first-of-its-kind drug that treats blood cancer. JakafiT (ruxolitinib) will treat patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. This drug was developed by Incyte in Wilmington at the Experimental Station campus. Sen. Carper encouraged the company to locate in Delaware in 2001 and subsequently expand its operation here to begin drug research in the First State.
“For years, Incyte has worked tirelessly to bring this innovative drug treatment to the many patients that are fighting the blood cancer myelofibrosis,” said Sen. Carper. “Since helping Incyte to come to Delaware a decade ago, I have been hopeful that this day would come. This is a great achievement for the entire Incyte team and the thousands of people suffering from myelofibrosis whose quality of life will be improved as a result of this medication.”